Evaluation of the Incremental Healthcare Economic Burden of Patients with Atrial Fibrillation Treated with Direct-Acting Oral Anticoagulants and Hospitalized for Major Bleeds in the USA

[1] Go AS(2001)Prevalence of diagnosed atrial fibrillation in adults: national implications for rhythm management and stroke prevention: the AnTicoagulation and Risk Factors in Atrial Fibrillation (ATRIA) Study JAMA 285 2370-2375

[2] Hylek EM(2006)Secular trends in incidence of atrial fibrillation in Olmsted County, Minnesota, 1980 to 2000, and implications on the projections for future prevalence Circulation 114 119-125

[3] Phillips KA(2011)Estimation of total incremental health care costs in patients with atrial fibrillation in the United States Circ Cardiovasc Qual Outcomes 4 313-320

[4] Miyasaka Y(2011)Rivaroxaban versus warfarin in nonvalvular atrial fibrillation N Engl J Med 365 883-891

[5] Barnes ME(2011)Apixaban versus warfarin in patients with atrial fibrillation N Engl J Med 365 981-982

[6] Gersh BJ(2013)Edoxaban versus warfarin in patients with atrial fibrillation N Engl J Med 369 2093-2104

[7] Kim MH(2018)Real-world comparison of bleeding risks among non-valvular atrial fibrillation patients prescribed apixaban, dabigatran, or rivaroxaban PLoS One 13 e0205989-498

[8] Johnston SS(2018)Comparison of major bleeding risk in patients with non-valvular atrial fibrillation receiving direct oral anticoagulants in the real-world setting: a network meta-analysis Curr Med Res Opin 34 487-1223

[9] Chu BC(2017)Incremental economic burden associated with major bleeding among atrial fibrillation patients treated with factor Xa inhibitors J Med Econ 20 1217-2962

[10] Dalal MR(2018)Medicare part D prescribing for direct oral anticoagulants in the United States: cost, use and the “rubber effect” PLoS One 13 e0198674-759

[1] Go AS(2001)Prevalence of diagnosed atrial fibrillation in adults: national implications for rhythm management and stroke prevention: the AnTicoagulation and Risk Factors in Atrial Fibrillation (ATRIA) Study JAMA 285 2370-2375

[2] Hylek EM(2006)Secular trends in incidence of atrial fibrillation in Olmsted County, Minnesota, 1980 to 2000, and implications on the projections for future prevalence Circulation 114 119-125

[3] Phillips KA(2011)Estimation of total incremental health care costs in patients with atrial fibrillation in the United States Circ Cardiovasc Qual Outcomes 4 313-320

[4] Miyasaka Y(2011)Rivaroxaban versus warfarin in nonvalvular atrial fibrillation N Engl J Med 365 883-891

[5] Barnes ME(2011)Apixaban versus warfarin in patients with atrial fibrillation N Engl J Med 365 981-982

[6] Gersh BJ(2013)Edoxaban versus warfarin in patients with atrial fibrillation N Engl J Med 369 2093-2104

[7] Kim MH(2018)Real-world comparison of bleeding risks among non-valvular atrial fibrillation patients prescribed apixaban, dabigatran, or rivaroxaban PLoS One 13 e0205989-498

[8] Johnston SS(2018)Comparison of major bleeding risk in patients with non-valvular atrial fibrillation receiving direct oral anticoagulants in the real-world setting: a network meta-analysis Curr Med Res Opin 34 487-1223

[9] Chu BC(2017)Incremental economic burden associated with major bleeding among atrial fibrillation patients treated with factor Xa inhibitors J Med Econ 20 1217-2962

[10] Dalal MR(2018)Medicare part D prescribing for direct oral anticoagulants in the United States: cost, use and the “rubber effect” PLoS One 13 e0198674-759